the pitch banner


Samantha Lee/Business Expert.


  • British expert system start-up Healx has actually simply raised a $56 million Series B led by among Europe’s greatest financiers, Atomico.
  • ” Initially we weren’t intending on doing a Series B this year however Atomico approached us and we were lined up in regards to our vision to scale rapidly into Europe,” CEO Dr Tim Guilliams informed Company Expert.
  • The Cambridge-based business just raised its Series An in 2015 and is seeking to broaden quickly with its unusual illness treatment programs in a market worth an approximated $220 billion.
  • Healx utilizes AI and ML software application to assist discover treatments for some 7,000 unusual illness which impact around 400 million individuals around the world and will utilize the financing to establish its accelerator program.
  • Click On This Link for more BI Prime stories

Cambridge, UK-based healthtech start-up Healx has actually simply raised a $56 million Series B led by among Europe’s greatest financiers to utilize expert system to deal with the world’s rarest illness.

The business establishes treatments for unusual illness utilizing exclusive expert system software application. It has actually raised from significant European financier Atomico, Global Brain, and Btov Partners as it wants to scale its offering. Healx approximates that some 400 million clients struggle with around 7,000 unusual illness around the world which will not be covered by conventional medical science.

It becomes part of a significant push into brand-new types of biological engineering and tech-led health options in what’s approximated to be a $220 billion market by Healx. Atomico primary Irina Haivas, a Healx board member, stated that the business’s mix of strong tech and drug know-how was a winning design in what she declares is a big and growing part of the marketplace.

The funds raised, simply a year after its $10 million Series A, will be utilized to release its international “Unusual Treatment Accelerator” program that includes treatments for vulnerable X syndrome, the leading hereditary reason for autism.

Previous Healx financiers, consisting of Balderton Capital, Amadeus Capital Partners, and angel financier Jonathan Milner likewise took part in the round.

” Initially we weren’t intending on doing a Series B this year however Atomico approached us and we were lined up in regards to our vision to scale rapidly into Europe,” Healx’s CEO and cofounder Dr Tim Guilliams informed Company Expert in an interview. “The typical clinician does not understand anything about the illness we’re handling and we’re approaching a huge issue, in a substantial market with really particular options.”

Healx was established in 2014 by Andreas Bender, David Brown (the co-inventor of Viagra and previous head of drug discovery at Roche) David Cavalla, and Guilliams, who established Cambridge Rare Illness Network (CRDN).

You can see the redacted pitch deck that protected Healx’s financing listed below: